301
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Re-evaluating osteoporosis and fracture risk in Crohn’s disease patients in the era of TNF-alpha inhibitors

ORCID Icon, , , &
Pages 168-172 | Received 15 Nov 2017, Accepted 06 Dec 2017, Published online: 13 Dec 2017

References

  • Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut. 1987;28:410–415.
  • Klaus J, Armbrecht G, Steinkamp M, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut. 2002;51:654–658.
  • Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795–841.
  • Ali T, Lam D, Bronze MS, et al. Osteoporosis in inflammatory bowel disease. Am J Med. 2009;122:599–604.
  • Targownik LE, Bernstein CN, Leslie WD. Inflammatory bowel disease and the risk of osteoporosis and fracture. Maturitas. 2013;76:315–319.
  • Ghishan FK, Kiela PR. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol. 2011;300:G191–G201.
  • Daniell HW. Osteoporosis and smoking. JAMA. 1972;221:509
  • Smith R. Corticosteroids and osteoporosis. Thorax. 1990;45:573–578.
  • Vestergaard P. Epilepsy, osteoporosis and fracture risk – a meta-analysis. Acta Neurol Scand. 2005;112:277–286.
  • Winkler A, Pressly TA, Wilson D. Androgen deficient osteoporosis. Mo Med. 1988;85:84–86.
  • Andersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol. 2016;28:420–425.
  • Zheng SX, Vrindts Y, Lopez M, et al. Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas. 1997;26:63–71.
  • Sang C, Zhang J, Zhang Y, et al. TNF-alpha promotes osteoclastogenesis through JNK signaling-dependent induction of Semaphorin3D expression in estrogen-deficiency induced osteoporosis. J Cell Physiol. 2017;232:3396–3408.
  • Veerappan SG, O'Morain CA, Daly JS, et al. Review article: the effects of antitumour necrosis factor-alpha on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:1261–1272.
  • Azzopardi N, Ellul P. Risk factors for osteoporosis in Crohn's disease: infliximab, corticosteroids, body mass index, and age of onset. Inflamm Bowel Dis. 2013;19:1173–1178.
  • Sugimoto K, Ikeya K, Iida T, et al. An increased serum N-Terminal telopeptide of type i collagen, a biochemical marker of increased bone resorption, is associated with infliximab therapy in patients with Crohn's disease. Dig Dis Sci. 2016;61:99–106.
  • Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013;369:754–762.
  • Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–1930.
  • Malutan AM, Dan M, Nicolae C, et al. Proinflammatory and anti-inflammatory cytokine changes related to menopause. Prz Menopauzalny. 2014;13:162–168.
  • Pacifici R. T cells and post menopausal osteoporosis in murine models. Arthritis Res Ther. 2007;9:102.
  • Roggia C, Gao Y, Cenci S, et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA. 2001;98:13960–13965.
  • Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332:305–311.
  • Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol. 2006;40:55–63.
  • Veerappan SG, Healy M, Walsh BJ, et al. Adalimumab therapy has a beneficial effect on bone metabolism in patients with Crohn's disease. Dig Dis Sci. 2015;60:2119–2129.
  • Veerappan SG, Healy M, Walsh B, et al. A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol. 2016;28:1335–1344.
  • Krieckaert CL, Nurmohamed MT, Wolbink G, et al. Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology (Oxford). 2013;52:547–553.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.